Dr Mitchell Glass discusses with BRR media the update on Invion’s phase II study of INV102 (nadolol) in asthma patients

Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to listen to Executive Vice President and Chief Medical Officer, Dr Mitchell Glass, as he provides further background to today’s announcement regarding interim blinded data and progress of Invion’s phase II clinical trial in patients with mild asthma. In this audiocast, Dr Glass discusses:

  • What the interim blinded data from the phase II asthma trial has shown;
  • The significance of safety signals in a clinical trial of a drug that is currently contraindicated in patients with chronic airway disease;
  • Next steps in Invion’s INV102 (nadolol) phase II clinical programs; and
  • How emerging data is underpinning and supporting the development of nadolol as both an oral treatment for smoking cessation and an inhaled treatment for COPD and cystic fibrosis.

To access the audiocast, please visit this link: www.brrmedia.com/event/127115

Posted in ASX Releases